The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

Eli Lilly is developing a groundbreaking drug, lepodisiran, to combat high LPA cholesterol levels prevalent in South Asians, ...

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp (a) inhibitor from China's Jiangsu Hengrui ...

We recently published an article titled Why These 15 Real Estate Stocks Are Plunging In 2025. In this article, we are going to take a look at where Logistic Properties of the Americas ...